

Mitochondrial DNA Copy Number and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Risk in Two Prospective Studies

Christopher Kim¹, Bryan A. Bassig¹, Wei Jie Seow¹, Wei Hu¹, Mark P. Purdue¹, Wen-Yi Huang¹, Chin-San Liu², Wen-Ling Cheng², Satu Männistö³, Roel Vermeulen⁴, Stephanie J. Weinstein¹, Unhee Lim⁵, H. Dean Hosgood⁶, Matthew R. Bonner⁷, Neil E. Caporaso¹, Demetrius Albanes¹, Qing Lan¹, and Nathaniel Rothman¹

Abstract

Background: Mitochondrial DNA copy number (mtDNA CN) may be modified by mitochondria in response to oxidative stress. Previously, mtDNA CN was associated with non-Hodgkin lymphoma (NHL) risk, particularly chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). We conducted a replication study in the Prostate, Lung, Colorectal, and Ovarian (PLCO) study and pooled with published ATBC (Alpha-Tocopherol, Beta-Carotene) data.

Methods: In PLCO, 292 NHL cases (95 CLL/SLL cases) and 301 controls were pooled with 142 NHL cases (47 CLL/SLL cases) and 142 controls from ATBC. Subjects answered a questionnaire and provided blood. DNA was extracted from prediagnostic peripheral white blood, and mtDNA CN assayed by quantitative polymerase chain reaction. Unconditional logistic regression estimated mtDNA CN and NHL risk by odds ratios (OR) and 95% confidence intervals (95% CI).

Results: Greater mtDNA CN was associated with increased risk of CLL/SLL among males in PLCO (3rd vs. 1st tertile: OR, 2.21; 95% CI, 1.03–4.72; P_{trend} : 0.049) and pooled (T3 vs. T1: OR, 3.12; 95% CI, 1.72–5.68; P_{trend} : 0.0002). Association was stronger among male smokers (P_{trend} : <0.0001) and essentially identical for cases diagnosed <6, >6–8, and >8 years from blood draw (pooled: $P_{\text{interaction}}$: 0.65). mtDNA CN and risk of other NHL subtypes and multiple myeloma showed no association.

Conclusions and Impact: Mitochondrial DNA CN was associated with risk of CLL/SLL in males/male smokers. The risk was observed among cases diagnosed as long as 8 years after blood draw. These results suggest that higher mtDNA CN may reflect a process involved in CLL/SLL development. *Cancer Epidemiol Biomarkers Prev*; 24(1); 148–53. ©2014 AACR.

Introduction

Mitochondria are the principal organelle in eukaryotic cells responsible for energy production through the generation of adenosine triphosphate (ATP) via the electron transport chain (ETC; ref. 1). Mitochondria have a singular circular mitochondrial DNA (mtDNA) molecule that is approximately 16k-bp long. As mitochondria age, generation of reactive oxygen species (ROS)

increases. This intracellular production of ROS increases oxidative stress, causing damage to DNA, inducing modification of the purine and pyrimidine bases, single- and double-strand breaks, and cross-links to other molecules (2). As mitochondria experience more oxidative stress, pro-inflammatory cytokine production increases (3), which has been associated with risk of non-Hodgkin lymphoma (NHL; ref. 4).

Mitochondrial DNA lacks the protective histones and repair capacity of nuclear chromosomal DNA (2). Expression and stability of mtDNA have been suggested to play a critical role in human pathogenesis due to deficiency in maintenance and stability of the ETC (5), and mitochondria may modify genomic copy number as a mechanism to cope with increased genomic instability and damage (6). Measurements in blood samples of subjects have shown that oxidative stress measurements by thiobarbituric acid-reactive substances, 8-hydroxy-2'-deoxyguanosine, and 4,977 bp deletions and mtDNA CN have been positively correlated (7).

Several studies have examined variation in mtDNA copy number (mtDNA CN) and cancer risk; most prospective studies have found a positive association, and retrospective studies have found an inverse association (8–17), including a strong association observed between increased mtDNA CN and risk of NHL, particularly CLL/SLL, in a prospective cohort study of Finnish male smokers (13) and Europeans (18). Liao and colleagues noted an increased risk in gastric cancer cases diagnosed recently in relation

¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. ²Neurology and Vascular and Genomic Center, Changhua Christian Hospital, Changhua, Taiwan. ³Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland. ⁴Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands. ⁵Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii. ⁶Albert Einstein College of Medicine, Yeshiva University, Bronx, New York. ⁷Department of Epidemiology and Environmental Health, State University of New York at Buffalo, Buffalo, New York.

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (<http://cebp.aacrjournals.org/>).

Q. Lan and N. Rothman co-supervised this work.

Corresponding Author: Christopher Kim, 9609 Medical Center Drive, MSSC 9771, Bethesda, MD 20892. Phone: 240-276-7440. E-mail: christopher.kim@nih.gov

doi: 10.1158/1055-9965.EPI-14-0753

©2014 American Association for Cancer Research.

to blood draw/entry into study (≤ 2 years) in a cohort of Chinese women (19), suggesting that mtDNA CN could be influenced by the result of disease, and more prospective data are needed. Contrastingly, low mtDNA CN has been associated with lung tumor (20), breast cancer (21), and ovarian cancer (22) progression.

To confirm previous findings of mtDNA CN and risk of NHL/CLL/SLL, we conducted a nested case-control study in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial and pooled previously published data (13) from the Alpha-Tocopherol, Beta-Carotene cancer prevention study (ATBC). In addition, we utilized the newest case definitions of NHL subtypes from the Pathology Working Group of the International Lymphoma (INTERLYMPH) Epidemiology Consortium (23) to update the previously published ATBC study.

Materials and Methods

Study subjects

The PLCO screening trial has been described in detail elsewhere (24). Briefly, PLCO is a large randomized trial to determine whether screening for these cancers reduces cause-specific mortality. A total of 154,910 males and females ages 55 to 74 years with no prior history of cancer were enrolled during 1993–2001 in 10 different centers around the United States. Self-administered questionnaire inquired information on demographics and risk factors as well blood specimens for intervention-arm participants. Within 2 hours of blood collection, specimens were processed and frozen at -70°C . The PLCO study was reviewed by the institutional review boards of the National Cancer Institute and the 10 study centers, and all participants provided written informed consent in accordance with the Declaration of Helsinki.

Cancer cases in the PLCO trial were identified through annual follow-up questionnaires and telephone calls. First primary cancers of the prostate, lung, colorectal, and ovarian were also identified through screening tests conducted in the first 6 years of the trial. We identified 301 cases of first primary lymphoid malignancies (244 NHL cases, 95 CLL/SLL cases, and 57 multiple myeloma cases) with serum collected at baseline from the screening arm in PLCO. These cases were confirmed by medical record review at each screening center. Controls were individually matched to cases (1:1 ratio) by age at baseline (5-year categories), sex, race, and interview/blood collection date (± 3 months) from among subjects who had not been diagnosed with any type of malignancy except nonmelanoma skin cancer at the time of the case diagnosis date.

The ATBC study has been described in detail (25). Briefly, 29,133 eligible male smokers, ages 50 to 69 years, were recruited from southwest Finland and randomized from 1985 to 1988 to determine whether supplementation with α -tocopherol or β -carotene reduced the incidence of lung and other cancers. At the first visit, the males completed interviews with a study nurse on basic demographic characteristics and whole blood was collected at follow-up (1992–1993). All cases of NHL were identified using the Finnish Cancer Registry, which provides virtually 100% of case ascertainment from the ATBC cohort (26). The hospital records of the identified cases were reviewed by an experienced study oncologist for confirmation of the lymphoma diagnosis. Through April 30, 2002, 142 individuals with incident cases of lymphoid neoplasms (122 NHL cases, 47 CLL/SLL cases, and 20 multiple myeloma cases) with an available prediagnostic blood specimen

for analysis were identified. Controls were individually matched to cases (1:1) on date of birth (± 5 years). In the previously published data from ATBC (13), 107 cases were utilized; updated INTERLYMPH and SEER classifications of neoplasms account for 15 NHL cases (12 CLL/SLL) that were not previously included in the analyses. The ATBC study was approved by institutional review boards at the National Cancer Institute and the National Public Health Institute of Finland. Participants provided written informed consent in accordance with the Declaration of Helsinki.

Histologic type was obtained by medical record abstraction or recorded by the tumor registrar at each participating medical center using standard ICD-O-2 codes that were re-coded to ICD-O-3. Subtypes of NHL were categorized by the most recent INTERLYMPH classification update from 2010 (23) utilizing the fifth hierarchical level (ATBC analyses were regrouped to this classification). When an ICD-O-3 code was recorded in the PLCO or ATBC records but not defined in INTERLYMPH, codes were identified using NCI's SEER classification for ICD-O-3 coding materials to classify the remaining subtypes (<http://seer.cancer.gov/icd-o-3/sitetype.icdo3.d20121205.pdf>). The subtype groupings were classified as follows: multiple myeloma (9731, 9732, 9733, 9734), CLL/SLL/B-PLL/MCL (9670, 9673, 9823, 9832, 9833; all cases were 9670 or 9823, referred to CLL/SLL throughout for simplicity), diffuse large B-cell lymphoma (DLBCL; 9678, 9679, 9680–9689, 9712, 9735, 9737, 9738), follicular (9690–9699) and other/NOS (9590, 9591, 9596, 9673, 9675, 9684, 9687, 9704, 9707, 9710, 9715, 9727, 9728, 9765, 9766, 9811–9812, 9820, 9835, 9836, 9940, 9970). Case histology by cohort is presented in Table 1.

Laboratory analysis

DNA was extracted from the peripheral white blood cells of the whole blood using the phenol-chloroform method (27), and fluorescence-based quantitative polymerase chain reaction determined mtDNA CN using the ratio of the estimation of threshold cycle number of *ND1*, a mitochondrial gene, and the *B-globin* gene, *HBB*, a nuclear gene (7). Samples for both studies were processed and assayed by the same laboratory. Cases and controls were blindly assayed consecutively within each batch. Blinded quality control duplicate samples (8 samples from 2 subjects) were interspersed in each batch to evaluate assay reproducibility. In the PLCO analysis, the overall coefficient of variation (CV) of this assay was 6.8%; 9 of 301 selected cases and 2 of 303 selected controls had poor quality DNA or the assay malfunctioned, leaving 292 cases and 301 controls in the final analysis. In the ATBC analysis, 142 matched sets of cases and controls were previously assayed, with an overall CV of 13% (13). In total, 434 cases and 443 controls comprised the pooled ATBC and PLCO analyses.

Statistical analysis

Differences in selected demographic characteristics between cases and controls were assessed using the Wilcoxon rank sum test for continuous variables and Pearson χ^2 test for categorical variables. Unconditional logistic regression models were used to generate odds ratios (OR) and 95% confidence intervals (95% CI) to estimate the association of mtDNA CN and risk of CLL/SLL. Polytomous logistic regression models were used in place of binary logistic regression in analyses stratified by NHL, subtypes (DLBCL, follicular, other/NOS), multiple myeloma, and time since blood draw. Cohort-specific distribution of mtDNA CN

Table 1. Baseline characteristics of lymphoid cases and controls in PLCO and ATBC nested case-control studies

Characteristics	PLCO				ATBC			
	Cases (n = 292) n (%)	CLL/SLL (n = 95) n (%)	Controls (n = 301) n (%)	P ^a	Cases (n = 142) n (%)	CLL/SLL (n = 47) n (%)	Controls (n = 142) n (%)	P ^a
Sex								
Male	178 (62%)	57 (60%)	185 (61%)	0.85	142 (100%)	47 (100%)	142 (100%)	—
Female	114 (38%)	38 (40%)	116 (39%)		—	—	—	
Tobacco use								
Current	116 (40%)	36 (38%)	130 (43%)	0.64	123 (87%)	36 (77%)	105 (74%)	0.56
Former	19 (6%)	10 (10%)	25 (8%)		19 (13%)	11 (23%)	37 (26%)	
Never	157 (54%)	49 (52%)	146 (49%)		—	—	—	
Male ever smoker								
Yes	90 (31%)	30 (32%)	109 (36%)	0.24	142 (100%)	47 (100%)	142 (100%)	—
No	202 (69%)	65 (68%)	192 (64%)		—	—	—	
Race								
White	278 (94%)	92 (97%)	282 (94%)	0.73	142 (100%)	47 (100%)	142 (100%)	—
Black	5 (2%)	2 (2%)	7 (2%)		—	—	—	
Other	9 (4%)	1 (1%)	12 (4%)		—	—	—	
NHL subtype								
DLBCL	48 (16%)				22 (15%)			
Follicular	41 (14%)				12 (8%)			
CLL/SLL	95 (33%)				47 (33%)			
Other/unknown	55 (19%)				41 (29%)			
Multiple myeloma	53 (18%)				20 (14%)			
Mean (SD) age in years	63.97 (5.29)	63.87 (5.34)	63.83 (5.4)	0.77	58.23 (4.81)	59.29 (4.74)	57.64 (4.79)	0.35
Mean (SD) years of follow-up	5.26 (2.44)	5.04 (2.51)	12.63 (2.15)	<0.0001	8.93 (3.25)	7.7 (2.98)	8.93 (3.25)	0.031
Mean (SD) BMI	27.55 (5.06)	27.01 (4.39)	27.29 (4.03)	0.44	26.36 (4.03)	26.08 (4.33)	26.37 (3.67)	0.66
Mean (SD) tobacco use (pack-years)	15.59 (25.7)	16.52 (25.71)	19.37 (27.17)	0.41	35.55 (17.24)	35.15 (16.21)	35.83 (17.04)	0.94
Mean (SD) mtDNA	144.3 (97.23)	144.81 (64.34)	144.2 (79.76)	0.33	126.1 (40.84)	137.13 (35.07)	117.7 (38.16)	0.0003
Median (25%–75% range), mtDNA	123 (92–166)	127 (101–176)	121 (89–172)		113 (96–154)	142 (107–161)	109 (93–133)	

^aAll *P* values compare CLL/SLL cases with controls; χ^2 for categorical variables; Wilcoxon rank sum for continuous variables.

among all controls was used to determine cutoff points for tertiles. In the pooled analysis, tertile groupings were maintained from each cohort to minimize any potential effects of lab drift. Unconditional model results were similar to conditional models, but to maximize statistical stability, unconditional models that utilized all controls were used for all analyses. All models compared the higher versus the lowest tertile of mtDNA. Models were adjusted for sex (male, female-PLCO, and pooled only), age (continuous), tobacco (pack-years), BMI (continuous), race (white, black, other-PLCO and pooled only), date of blood draw (year), and study (PLCO, ATBC). After adjustment for supplementation group in ATBC, results were similar to nonadjusted estimates; thus, supplement group was left out of the final models. We also conducted analyses stratifying by sex (male, female) and smoking status (ever, never). In addition, we conducted stratified analyses in males by time since blood draw to diagnosis (≤ 6 years, > 6 –8 years, > 8 years). P_{trend} utilized the tertiles of mtDNA modeled continuously. Significance tests were two-sided at the 0.05 level. All analyses were conducted in SAS 9.22 (SAS Institute).

Results

The demographic characteristics were fairly similar between the lymphoid cases, CLL/SLL cases, and controls for both studies (Table 1). Sex, tobacco, race, age, BMI, and pack-years of tobacco smoked were not statistically different between CLL/SLL cases and controls ($P > 0.05$). mtDNA CN was significantly higher in cases than in controls in the ATBC study ($P < 0.05$). Being male and pack-years of smoking were negatively associated with mtDNA CN among controls (pooled: linear regression, β : -37.97 , -0.26 , respectively; $P < 0.05$). The range of mtDNA CN was wider in PLCO than in ATBC, and the median mtDNA CN was greater in

PLCO (median of controls, 121) than in ATBC (median of controls, 109). There was no significant difference ($P = 0.11$) in mtDNA CN comparing male smoker controls in PLCO (mean, 128.3) versus controls in ATBC (mean, 117.7; data not shown).

Mitochondrial DNA copy number was not associated with risk of NHL in PLCO (Supplementary Table S1). Mitochondrial DNA copy number was elevated but not significantly associated with risk of CLL/SLL in PLCO (highest vs. lowest tertile: OR, 1.53; 95% CI, 0.84–2.81), but was significantly associated in the pooled population (OR, 2.25; 95% CI, 1.35–3.74; Table 2). In males, the elevated risk of CLL/SLL was observed in both studies individually and the pooled analysis ($P_{\text{trend}} < 0.05$, $P_{\text{interaction}}$ by sex < 0.05), especially among smokers (highest vs. lowest tertile: OR, 4.28; 95% CI, 2.06–8.88). When PLCO analyses were restricted to the characteristics of the ATBC population (males and ever smokers), CLL/SLL risk was elevated (OR, 2.93; 95% CI, 1.01–8.51). Compared with the PLCO population, the effect estimates in the ATBC population were greater, although not statistically different (P , 0.13). There was suggestion of no association in nonsmokers, and there was no association in females. Additional stratified analyses by time to diagnosis from blood draw among males showed a consistent elevation of risk at ≤ 6 , 6–8, and > 8 years in the pooled population ($P_{\text{interaction}}$: 0.65, Table 3). Analyses with non-whites removed were not substantially different, and stratified analyses by age and BMI were not dramatically different or statistically unstable (data not shown).

When the analyses were conducted for NHL, NHL subtypes, or multiple myeloma, no significant associations were observed in the pooled data ($P_{\text{trend}} > 0.05$; Supplementary Table S1). Analyses for overall NHL and mtDNA CN associations stratified by sex, smoking status, and time from blood draw to diagnosis were unremarkable (Supplementary Tables S2 and S3).

Table 2. Association of mtDNA CN and risk of CLL/SLL in each cohort by sex and smoking status

Cohort characteristics	mtDNA ^a	PLCO			ATBC			Pooled		
		Cases	Controls	OR ^b (95% CI)	Cases	Controls	OR ^c (95% CI)	Cases	Controls	OR ^d (95% CI)
All CLL/SLL	1	22	100	1 (ref)	5	48	1 (ref)	27	148	1 (ref)
	2	38	98	1.77 (0.97-3.23)	14	45	3.18 (1.03-9.83)	52	143	1.99 (1.18-3.36)
	3	35	103	1.53 (0.84-2.81)	28	49	5.55 (1.89-16.25)	63	152	2.25 (1.35-3.74)
			<i>P</i> _{trend}	0.21		<i>P</i> _{trend}	0.0017		<i>P</i> _{trend}	0.0022
Male	1	14	72	1 (ref)	5	48	1 (ref)	19	120	1 (ref)
	2	21	61	1.79 (0.84-3.85)	14	45	3.18 (1.03-9.83)	35	106	2.11 (1.13-3.92)
	3	22	52	2.21 (1.03-4.72)	28	49	5.55 (1.89-16.25)	50	101	3.12 (1.72-5.68)
			<i>P</i> _{trend}	0.049		<i>P</i> _{trend}	0.01		<i>P</i> _{trend}	0.0002
Female	1	8	28	1 (ref)	—	—	—	8	28	1 (ref)
	2	17	37	1.66 (0.60-4.56)	—	—	—	17	37	1.66 (0.60-4.56)
	3	13	51	0.84 (0.30-2.33)	—	—	—	13	51	0.84 (0.30-2.33)
			<i>P</i> _{trend}	0.59		<i>P</i> _{trend}	—		<i>P</i> _{trend}	0.55
Ever smoker	1	11	59	1 (ref)	5	48	1 (ref)	16	107	1 (ref)
	2	16	44	2.19 (0.91-5.27)	14	45	3.18 (1.03-9.83)	30	89	2.32 (1.18-4.55)
	3	19	52	1.91 (0.82-4.41)	28	49	5.55 (1.89-16.25)	47	101	2.94 (1.56-5.55)
			<i>P</i> _{trend}	0.14		<i>P</i> _{trend}	0.01		<i>P</i> _{trend}	0.001
Never smoker	1	11	41	1 (ref)	—	—	—	11	41	1 (ref)
	2	22	54	1.56 (0.68-3.62)	—	—	—	22	54	1.56 (0.68-3.61)
	3	16	51	1.22 (0.49-2.98)	—	—	—	16	51	1.22 (0.50-2.98)
			<i>P</i> _{trend}	0.73		<i>P</i> _{trend}	—		<i>P</i> _{trend}	0.73
Male ever smoker	1	6	45	1 (ref)	5	48	1 (ref)	11	93	1 (ref)
	2	11	31	2.87 (0.96-8.59)	14	45	3.18 (1.03-9.83)	25	76	2.94 (1.36-6.38)
	3	13	33	2.93 (1.01-8.51)	28	49	5.55 (1.89-16.25)	41	82	4.28 (2.06-8.88)
			<i>P</i> _{trend}	0.052		<i>P</i> _{trend}	0.01		<i>P</i> _{trend}	<0.0001
Any female/male nonsmokers	1	16	53	1 (ref)	—	—	—	16	53	1 (ref)
	2	27	67	1.32 (0.64-2.72)	—	—	—	27	67	1.32 (0.64-2.72)
	3	22	70	1.01 (0.48-2.13)	—	—	—	22	70	1.01 (0.48-2.13)
			<i>P</i> _{trend}	0.95		<i>P</i> _{trend}	—		<i>P</i> _{trend}	0.95
			<i>P</i> _{interaction}	0.11		<i>P</i> _{interaction}	—		<i>P</i> _{interaction}	0.011

NOTE: Bold signifies statistical significance at $P < 0.05$ or confidence interval does not contain 1.0.^aTertiles: PLCO: 1, <99; 2, >99-145; 3, >145; ATBC: 1, <97; 2, >97-121; 3, >121.^bAdjusted for sex, age, tobacco pack-years, BMI, race, and date of blood draw with exception of stratified variable.^cAdjusted for age, tobacco pack-years, BMI, and date of blood draw with exception of stratified variable.^dAdjusted for sex, age, tobacco pack-years, BMI, race, date of blood draw, and cohort with exception of stratified variable.*P*_{trend} calculated with the tertiles of mtDNA categories.

Discussion

We pooled data from two prospective studies that consisted of new data from PLCO and previously published data from ATBC (13). We found consistent evidence of an association between increased mtDNA CN and CLL/SLL risk among males and male smokers in the PLCO study and the pooled study. By pooling data, we were able to observe the mtDNA-CLL/SLL risk association in cases diagnosed as long as 8+ years after baseline blood draw. Similar to data previously published (13, 18), these results suggest mtDNA CN could reflect a process that reflects CLL/SLL development. There was no evidence of an association between mtDNA CN and CLL/SLL in nonsmokers; similarly, there was no observed association in females, although limited by few cases. We observed no association with mtDNA CN and risk of overall NHL, other NHL subtypes, or multiple myeloma risk.

In general, studies of mtDNA CN and risk of cancer have observed a positive association at various sites in prospective studies: lung (9, 16), cervix (11), colorectal (14, 17), and pancreas (15). One prospective study did not observe an overall association with gastric cancer risk in females, but cases diagnosed within two years of blood draw had an increased risk, suggesting that mtDNA CN elevation was an effect of the disease (19). Consistent with

other prospective studies, but unlike the aforementioned gastric cancer study (19), this study observed an mtDNA CN association with CLL/SLL risk in male smokers, similar to a previously published study (13). However, the strength of the association was slightly weaker in the new PLCO data and more similar to a study in Europeans (18). As leukocytes are from the same target tissue as CLL/SLL, mtDNA measured leukocytes could be a direct indication of mitochondrial activity and regulation, which could be a reflection of a disease process that results from genomic damage, oxidative stress, and inflammation occurring in the lymphatic system. Studies where mtDNA was measured in subjects with disease, inverse associations were observed in oral cancer (8), soft-tissue sarcoma (10), and renal cell carcinoma (12) and tumor progression (20-22), suggesting mtDNA CN levels decrease as cancer progresses. One study of colorectal cancer was retrospective, but found a positive association with mtDNA CN (13).

Although stratified analyses in other reports have been limited, several studies of mtDNA CN and cancer risk have observed significant associations among smokers and males but not in females. Two studies found the association was strongest among smokers for oral cancer and pancreatic cancer (8, 15). Two studies conducted in male-only populations observed significant associations with lung cancer and pancreatic cancer (9, 15). Three

Table 3. Association of mtDNA CN and risk of CLL/SLL by cohort and years from blood draw to diagnosis

Cohort Subtype	mtDNA ^a	PLCO			ATBC			Pooled		
		Cases	Controls	OR ^b (95% CI)	Cases	Controls	OR ^c (95% CI)	Cases	Controls	OR ^d (95% CI)
Years from diagnosis to blood draw (males)										
≤6 years										
	1	9	72	1 (ref)	0	48	—	9	120	1 (ref)
	2	11	61	1.49 (0.58–3.88)	3	45	—	14	106	1.81 (0.75–4.40)
	3	12	52	1.87 (0.73–4.76)	9	49	—	21	101	3.13 (1.35–7.25)
			<i>P</i> _{trend}	0.19					<i>P</i> _{trend}	0.0078
>6–8 years										
	1	3	72	1 (ref)	2	48	1 (ref)	5	120	1 (ref)
	2	5	61	2.06 (0.46–9.19)	1	45	0.69 (0.056–8.44)	6	106	1.47 (0.43–5.02)
	3	5	52	2.33 (0.53–10.27)	9	49	5.72 (1.05–31.23)	14	101	3.44 (1.19–9.99)
			<i>P</i> _{trend}	0.27		<i>P</i> _{trend}	0.019		<i>P</i> _{trend}	0.018
>8 years										
	1	2	72	1 (ref)	3	48	1 (ref)	5	120	1 (ref)
	2	5	61	2.64 (0.48–14.56)	10	45	3.53 (0.89–13.89)	15	106	3.08 (1.07–8.89)
	3	5	52	3.36 (0.62–18.22)	10	49	3.16 (0.79–12.61)	15	101	3.15 (1.09–9.11)
			<i>P</i> _{trend}	0.16		<i>P</i> _{trend}	0.13		<i>P</i> _{trend}	0.036
			<i>P</i> _{interaction}	0.58		<i>P</i> _{interaction}	0.67		<i>P</i> _{interaction}	0.65

NOTE: Bold signifies statistical significance at $P < 0.05$ or confidence interval does not contain 1.0.

^aTertiles: PLCO: 1, <99; 2, >99–145; 3, >145; ATBC: 1, <97; 2, >97–121; 3, >121.

^bPolytomous regression: adjusted for sex, age, tobacco pack-years, BMI, race, and date of blood draw.

^cPolytomous regression: adjusted for age, tobacco pack-years, BMI, and date of blood draw.

^dPolytomous regression: adjusted for sex, age, tobacco pack-years, BMI, race, date of blood draw, and cohort.

*P*_{trend} calculated with the tertiles of mtDNA categories.

studies did not find significant associations among females for gastric cancer (entire study population was female; ref. 19), renal cell carcinoma (~40% of study was female; ref. (12), and colorectal cancer (~40% cases and ~60% controls of study were female; ref. 17). However, due to relatively few females in our study, the analyses by sex were somewhat underpowered. Thus, we cannot state definitively that there was no association in females—only that there was limited suggestion of an association.

Male smokers had increased risk of CLL/SLL when mtDNA CN was elevated. Tobacco smoking (PLCO: ever, 133; never, 155) and being male (PLCO: males, 115; females, 137) were negatively associated with mtDNA CN in controls in this study. Similar trends by sex and smoking status were also observed in a population of Koreans (28). Because male smokers had a lower baseline mtDNA CN, and male smokers with higher mtDNA CN were at increased risk of CLL/SLL, these individuals may have genomic characteristics that are ideal for CLL/SLL development. Mitochondrial DNA genomes from CLL/SLL patients contain high levels of mtDNA content (29), are very stable, and can create genomic copies with deletions and mutations (30) without undergoing apoptosis or senescence.

In the time-based analyses, the mtDNA CN association was similar across several time points up to 8 years after blood draw until diagnosis, which suggests that mtDNA CN could reflect a risk factor for CLL/SLL development. In addition, approximately 20% ($n = 27$ of 142) of cases were in the first tertile, a disproportionately small proportion of cases. Although these analyses suggest mtDNA CN could be an etiologic biomarker in CLL/SLL risk, the number of cases available for these stratified analyses were somewhat sparse, so these results should be interpreted with caution.

Individuals with asymptomatic CLL/SLL, mtDNA CN could be an indicator of disease development. Precursor condition to CLL/SLL, monoclonal B-cell lymphocytosis, is detectable in CLL/SLL patients up to 77 months before diagnosis (31). But in healthy individuals, mtDNA CN and lymphocytes were not correlated ($r = 0.029$, $P = 0.72$; $n = 140$), suggesting that mtDNA CN is not just a surrogate marker of lymphocytosis.

The primary strengths of this study were due to the prospective designs of the PLCO and ATBC studies. All subjects in this study were recruited before diagnosis of any cancer, permitting analyses of associations stratified by the time of blood collection in relation to diagnosis. We assessed mtDNA in white blood cells, the target tissue for CLL/SLL. We utilized the latest revision of the INTER-LYMPH working group definitions for histologic subtype classifications of NHL (23), which allowed for more specific analyses of lymphoma subtypes. These revised classifications allowed for more accurate analyses of what are heterogeneous diseases. The primary weakness of this study was the single measurement of mtDNA CN. Copy number could change over time, and this study was unable to determine intrapersonal variation over time. Exactly how mtDNA changes as disease development progresses is currently unclear. In addition, there may be residual confounding that may alter mtDNA CN. There was limited evidence of an association in women and nonsmokers in PLCO, but only 39% ($n = 230$) of the study subjects were female and 52% ($n = 303$) were nonsmokers. Smaller sample size of females and nonsmokers compared with males and smokers (particularly when combined with ATBC study subjects) restricted the statistical stability of stratified analyses.

In conclusion, we observed that mtDNA CN was associated with risk of developing CLL/SLL in males and male smokers in PLCO, which replicated the results previously found in ATBC. After pooling PLCO and ATBC data, the association was observable as long as 8 years after entry into the study, suggesting that mtDNA CN may reflect a process that contributes to CLL/SLL development.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: M.R. Bonner, Q. Lan, N. Rothman
Development of methodology: C.-S. Liu, W.-L. Cheng, N. Rothman
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C. Kim, M.P. Purdue, W.-Y. Huang, S. Männistö, S.J. Weinstein, D. Albanes, Q. Lan, N. Rothman

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C. Kim, W.-Y. Huang, R. Vermeulen, H.D. Hosgood, Q. Lan, N. Rothman

Writing, review, and/or revision of the manuscript: C. Kim, B.A. Bassig, W.J. Seow, W. Hu, M.P. Purdue, W.-Y. Huang, S. Männistö, R. Vermeulen, S.J. Weinstein, U. Lim, H.D. Hosgood, N.E. Caporaso, D. Albanes, Q. Lan, N. Rothman

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C. Kim, W. Hu, W.-Y. Huang

Study supervision: Q. Lan, N. Rothman

Grant Support

This study was supported by the NIH intramural research program.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 2, 2014; revised September 17, 2014; accepted October 3, 2014; published OnlineFirst October 7, 2014.

References

- Hatefi Y. The mitochondrial electron transport and oxidative phosphorylation system. *Annu Rev Biochem* 1985;54:1015–69.
- Lee HC, Wei YH. Oxidative stress, mitochondrial DNA mutation, and apoptosis in aging. *Exp Biol Med (Maywood)* 2007;232:592–606.
- Naik E, Dixit VM. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. *J Exp Med* 2011;208:417–20.
- Purdue MP, Lan Q, Bagni R, Hocking WG, Baris D, Reding DJ, et al. Prediagnostic serum levels of cytokines and other immune markers and risk of non-Hodgkin lymphoma. *Cancer Res* 2011;71:4898–907.
- Shadel GS. Expression and maintenance of mitochondrial DNA: new insights into human disease pathology. *Am J Pathol* 2008;172:1445–56.
- Lee HC, Yin PH, Lu CY, Chi CW, Wei YH. Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells. *Biochem J* 2000;348 Pt 2:425–32.
- Liu CS, Tsai CS, Kuo CL, Chen HW, Lii CK, Ma YS, et al. Oxidative stress-related alteration of the copy number of mitochondrial DNA in human leukocytes. *Free Radic Res* 2003;37:1307–17.
- Mondal R, Ghosh SK, Choudhury JH, Seram A, Sinha K, Hussain M, et al. Mitochondrial DNA copy number and risk of oral cancer: a report from northeast India. *PLoS One* 2013;8:e57771.
- Hosgood HD 3rd, Liu CS, Rothman N, Weinstein SJ, Bonner MR, Shen M, et al. Mitochondrial DNA copy number and lung cancer risk in a prospective cohort study. *Carcinogenesis* 2010;31:847–9.
- Xie H, Lev D, Gong Y, Wang S, Pollock RE, Wu X, et al. Reduced mitochondrial DNA copy number in peripheral blood leukocytes increases the risk of soft tissue sarcoma. *Carcinogenesis* 2013;34:1039–43.
- Warowicka A, Kwasniewska A, Gozdicka-Jozefiak A. Alterations in mtDNA: a qualitative and quantitative study associated with cervical cancer development. *Gynecol Oncol* 2013;129:193–8.
- Mondal R, Hofmann JN, Colt JS, Hoxha M, Ruterbusch JJ, Davis FG, et al. A case-control study of peripheral blood mitochondrial DNA copy number and risk of renal cell carcinoma. *PLoS One* 2012;7:e43149.
- Lan Q, Lim U, Liu CS, Weinstein SJ, Chanock S, Bonner MR, et al. A prospective study of mitochondrial DNA copy number and risk of non-Hodgkin lymphoma. *Blood* 2008;112:4247–9.
- Qu FL, Liu XN, Zhou F, Yang HS, Bao GQ, He XL, et al. Association between mitochondrial DNA content in leukocytes and colorectal cancer risk: a case-control analysis. *Cancer* 2011;117:3148–55.
- Lynch SM, Weinstein SJ, Virtamo J, Lan Q, Liu CS, Cheng WL, et al. Mitochondrial DNA copy number and pancreatic cancer in the alpha-tocopherol beta-carotene cancer prevention study. *Cancer Prev Res* 2011;4:1912–9.
- Bonner MR, Shen M, Liu CS, Divita M, He X, Lan Q. Mitochondrial DNA content and lung cancer risk in Xuan Wei, China. *Lung Cancer* 2009;63:331–4.
- Thyagarajan B, Wang RW, Barcelo H, Koh WP, Yuan JM. Mitochondrial copy number is associated with colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev* 2012;21:1574–81.
- Hosnijeh FS, Lan Q, Rothman N, Liu CS, Cheng WL, Nieters A, et al. Mitochondrial DNA copy number and future risk of B-cell lymphoma in a nested case-control study in the prospective EPIC cohort. *Blood* 2014;124:530–5.
- Liao LM, Baccarelli A, Shu XO, Gao YT, Ji BT, Yang G, et al. Mitochondrial DNA copy number and risk of gastric cancer: a report from the Shanghai women's health study. *Cancer Epidemiol Biomarkers Prev* 2011;20:1944–9.
- Lin CS, Wang LS, Tsai CM, Wei YH. Low copy number and low oxidative damage of mitochondrial DNA are associated with tumor progression in lung cancer tissues after neoadjuvant chemotherapy. *Interact Cardiovasc Thorac Surg* 2008;7:954–8.
- Yu M, Zhou YL, Shi YR, Ning LS, Yang Y, Wei XY, et al. Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. *Iubmb Life* 2007;59:450–7.
- Wang Y, Liu VW, Xue WC, Cheung AN, Ngan HY. Association of decreased mitochondrial DNA content with ovarian cancer progression. *Br J Cancer* 2006;95:1087–91.
- Turner JJ, Morton LM, Linet MS, Clarke CA, Kadin ME, Vajdic CM, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. *Blood* 2010;116:e90–8.
- Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, et al. Methods for etiologic and early marker investigations in the PLCO trial. *Mutat Res-Fund Mol M* 2005;592:147–54.
- The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. *Ann Epidemiol* 1994;4:1–10.
- Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, Virtamo J. The Finnish cancer registry as follow-up source of a large trial cohort—accuracy and delay. *Acta Oncol* 2002;41:381–8.
- Garcia-Closas M, Egan KM, Abruozzo J, Newcomb PA, Titus-Ernstoff L, Franklin T, et al. Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. *Cancer Epidemiol Biomarkers Prev* 2001;10:687–96.
- Lee JY, Lee DC, Im JA, Lee JW. Mitochondrial DNA copy number in peripheral blood is independently associated with visceral fat accumulation in healthy young adults. *Int J Endocrinol* 2014;2014:586017.
- Carew JS, Nawrocki ST, Xu RH, Dunner K, McConkey DJ, Wierda WG, et al. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. *Leukemia* 2004;18:1934–40.
- Cerezo M, Bandelt HJ, Martin-Guerrero I, Ardanaz M, Vega A, Carracedo A, et al. High mitochondrial DNA stability in B-cell chronic lymphocytic leukemia. *PLoS One* 2009;4:e7902.
- Landgren O, Albitar M, Ma WL, Abbasi F, Hayes RB, Ghia P, et al. B-cell clones as early markers for chronic lymphocytic leukemia. *New Engl J Med* 2009;360:659–67.